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ABSTRACT: The development of lipopeptides (lipidated peptides) for
vaccines is discussed, including their role as antigens and/or adjuvants.
Distinct classes of lipopeptide architectures are covered including simple
linear and ligated constructs and lipid core peptides. The design,
synthesis, and immunological responses of the important class of glycerol-
based Toll-like receptor agonist lipopeptides such as Pam3CSK4, which
contains three palmitoyl chains and a CSK4 hexapeptide sequence, and
many derivatives of this model immunogenic compound are also
reviewed. Self-assembled lipopeptide structures including spherical and
worm-like micelles that have been shown to act as vaccine agents are also
described. The work discussed includes examples of lipopeptides
developed with model antigens, as well as for immunotherapies to treat
many infectious diseases including malaria, influenza, hepatitis, COVID-
19, and many others, as well as cancer immunotherapies. Some of these
have proceeded to clinical development. The research discussed highlights the huge potential of, and diversity of roles for,
lipopeptides in contemporary and future vaccine development.
1. INTRODUCTION
Vaccination has been a highly successful life-saving method to
prevent viral infections, since its development by Jenner in 1796
to treat smallpox, which has now been eradicated. Vaccines
based on live, attenuated pathogens have been developed for
many diseases; however, for other infections, such vaccines have
not been successful or they are ineffective since they fail to
provide long-lasting immunity (for example, influenza). In this
case, vaccines that use inactivated viruses or other subunits may
be created. The current COVID-19 pandemic has focused
attention on the impact of viral disease on human society and
already vaccines have been developed, remarkably rapidly, based
on mRNA technology (the genetic material is delivered in
liposomes) or the use of genetically modified (nonhuman)
adenovirus carriers (which incorporate spike protein genes), or
simply nanoparticle formulations containing virus spike protein
subunits as well as whole inactivated viruses. Further
information on this is widely available.1−6 Peptides and
lipopeptides are attractive in the development of vaccines,
both as antigens and as adjuvants. Peptide and lipopeptide
antigens can be developed based on sequences from antigenic
proteins, and they can be used to stimulate cell surface receptors
in a highly specific manner. Peptides offer advantages in the ease
of design and preparation using automated synthesis methods,
and they can also be conjugated to lipids and other molecules in
the development of adjuvants (or for antigen presentation) in
subunit vaccines. Conjugates of peptides and lipids, giving
lipidated peptides, termed lipopeptides, are the focus of the
current Review which discusses various approaches to the
synthesis and application of these molecules, a type of peptide
amphiphile. Peptides are relatively inexpensive and safe to
produce and can be synthesized at high purity, avoiding
contaminants such as lipopolysaccharides that can be present
in bioderived protein materials. A further feature of certain
classes of peptide-based molecules including lipopeptides is
their propensity to self-assemble into nanostructures such as
fibrils, micelles, and other structures.7−13 This property is of
interest because it leads to presentation of bioactive peptide
motifs at high density, leading potentially to improved antigen
and/or adjuvant efficacy, and some examples utilizing this
strategy are discussed in this Review. As yet, lipopeptide-based
vaccines are not used in clinical practice, although several
peptide-based vaccines have reached clinical trials and/or are
currently in active development.14−19 Many vaccines require
formulation with adjuvants, which are biomolecules that
stimulate immune responses in order to enhance the activity
of a vaccine. The roles of lipopeptides as antigens and/or
adjuvants is the focus of the current Review, and it includes the
important class of self-adjuvanting lipopeptides, which incor-
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porate both antigen and adjuvant activities. This Review does
not consider proteins or lipoproteins and is focused on
lipopeptides. Although there is no rigorous distinction between
long peptides and proteins, here we consider peptide-based
systems with less than about 100 residues.
Potential treatments for cancer also include novel immuno-
therapies. Cancer immunotherapies include potential vaccines,
monoclonal antibodies, T cell transfer therapy including CAR
(chimeric antigen receptor) T cell therapy, immune checkpoint
inhibitors (which modulate immune response), and immune
system modulators such as cytokines (for example, interferons
and interleukins). Lipopeptides have potential roles in many of
these approaches; in particular, TLR (Toll-like receptor) agonist
peptide-based molecules have attracted attention in cancer
immunotherapies, as discussed in more detail here, and in a
recent review focused on lipopeptides with applications as
adjuvants for cancer vaccines.20
This Review is organized as follows. Section 2 provides a brief
overview of the immune system and provides the background on
the cellular processes associated with the immune response, as
well as introducing key terminology. Section 3 concerns ligated
lipopeptides, in which lipid chains and peptides are coupled by
ligation methods. Section 4 covers TLR agonist lipopeptides,
one of the most intensely researched types of peptide
amphiphiles, because some of this class provoke a strong and
specific immune response, and indeed such molecules are used
as model TLR agonists. Section 5 discusses lipid core peptides
which havemore complex architectures than those of ligated and
TLR agonist lipopeptides, indeed generally offering a multi-
valent presentation of peptide epitopes. Lipopeptide micelle
self-assembled structures relevant to immunotherapies are
discussed in section 6. Concluding remarks in section 7 close
this Review.
2. BRIEF OVERVIEW OF THE IMMUNE SYSTEM,
INTRODUCING KEY TERMS
The immune system comprises the innate and adaptive systems.
The innate immune system relies on macrophages, neutrophils,
Figure 1. Cell types and other structures and processes involved in innate and adaptive immunity, which are referred to in this Review. From ref 18.
Published by the Royal Society of Chemistry.
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natural killer cells, dendritic cells, and others. The adaptive
immune system is activated by the presentation of antigens by
antigen-presenting cells (APCs) of the innate immune system.
Antigen presentation involves the binding of antigen to the
major histocompatibility complex (MHC), the complex then
being transported to the cell surface where it is presented and is
capable of recognition by a T cell receptor (TCR). This receptor
binds peptides presented by class I or class II major
histocompatibility complexes (also known as human leukocyte
antigen, HLA, for humans) on APCs (Figure 1). Whole antigens
are processed by proteolysis by APCs into short peptides (8−11
residues in length for class IMHCs and 11−30 residues in length
for class II MHCs), which are presented via MHCs at APC
surfaces.19 TCRs that are specific for particular peptide epitopes
then bind the peptide−MHC complexes, and a variety of
proteins at the T cell/APC interface orchestrate expansion of
clones of the T cells.
There are two types of MHC, one is involved with
intracellular peptides from the cytosol (MHC class I), while
MHC class II molecules bind peptides in endocytotic vesicles
after internalization. The MHC-I/peptide complex activates
cytotoxic T cells (Tc or killer T cells or cytotoxic T-lymphocyte
CTL, a type of white blood cell) via TCRs, these cells also
expressing CD8+ co-receptors (Figure 1) (here, CD refers to
cluster of differentiation, a class of cell surface glycoproteins that
can act as receptors or ligands). On the other hand, presentation
of antigens via MHC class II is to CD4+ T cells (Th helper T
cells, another type of white blood cell which sends signals to
other cells including Tc cells) (Figure 1). Only specific types of
APCs such as dendritic cells, B cells, or macrophages present
MHC-II at high levels, so expression of MHC-II molecules is
more cell-specific than MHC-I.
The innate immune system relies on pattern recognition
receptors (PRRs) to detect infecting microbes (Figure 1). PRRs
are present in germline cells. They can detect a wide range of
pathogens, although they lack the specificity of somatic T and B
cells. Most adjuvants are ligands for PRRs. The innate immune
response involves the recognition by PRRs of pathogen-
associated molecular patterns (PAMPs) which include TLRs,
NOD-like receptors (NLRs), C-type lectin agonists (CLRs),
RIG-I (retinoic acid-inducible gene I), stimulator of interferon
(IFN) genes (STINGs), and others.21−23 Adjuvants based on
these and other PAMPs can enhance the immune response (act
as agonists) by interacting with PRRs on antigen-presenting
cells. PAMPs elicit specific antigen presentation and cytokine
production. The role of TLRs which are a key target for
lipopeptides, as discussed later in this Review, has been reviewed
extensively.24−27 PRRs signal through a variety of pathways
involving distinct intermediates and key transcriptional factors
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B
cells), and interferon regulatory factors IRF-3 and IRF-7 (IRFs
primarily regulate type I interferons, IFNs, in the host after
pathogen infection) are activated, leading to the production of
cytokines and chemokines that prime and expand the immune
response.
The activated adaptive immune system relies on antigen-
recognizing species including T cells, B cells, dendritic cells, and
antibodies (immunoglobulins). As mentioned above, the
adaptive immune system produces T-helper cells which release
cytokines to “help” other immune cells. T-Helper cells
proliferate into differentiated Th1 cells or Th2 cells (Figure
1). The former lead to a cell-mediated response and the latter to
a humoral response which refers to the production of antibodies
and antimicrobial peptides and other agents in extracellular fluid
(and is also known as antibody-mediated immunity). The main
effector cells of Th1 immunity are macrophages as well as CD8+
T cells, IgG B cells, and IFN-γ CD4+ T cells. The main effector
cells for Th2 are leucocytes (white blood cells) including
basophils, eosinophils, and mast cells as well as B cells and IL-4/
IL-5 CD4+ T cells. Th1 cells produce cytokines including INF-γ
(interferon-gamma) and TNF-β (tumor necrosis factor-beta).
The Th2 response leads to interleukin cytokines including IL-4,
IL-5, IL-6, IL-9, IL-10, and IL-13. Th1-stimulated IFN-γ
increases the production of IL-12 by dendritic cells and
macrophages.
The activity of a vaccine may be enhanced using adjuvants,
and adjuvant development is currently attracting immense
interest as a means to substantially boost the performance of
vaccines active against a number of diseases. Many vaccines
confer humoral immunity, although adjuvants have been/are
being developed to stimulate cellular (Th1) immunity.21 The
most effective licensed vaccines elicit persistent T cell and B cell
memory as well as long-term antigen-specific antibody responses
by plasma cells.28 Adjuvants are used to increase antibody
production or to modulate the adaptive response. They boost
the performance of vaccines, enabling a lower dose of antigen
and/or a smaller number of required vaccinations. They hence
increase the level of immunization within the general population
that has been vaccinated and can boost immunity for groups
with lowered responsiveness such as older or infant
populations.21 As well as generally boosting the immune
response, adjuvants can be used to adjust the nature of the
immune response, for example, to change the Th1 versus Th2
response (so-called polarization of helper T cells) or the balance
of cytotoxic T cells versus helper CD4+ T cells or T cell memory
as well as altering the rate of immune response and its
specificity.21 The type of adjuvant selected will depend on the
nature of the desired CD4+ T cell response. Adjuvants should
elicit a protective CD8+ response depending on the type of
vaccine. Vaccines that cause direct infection of cells including
viral carriers or RNA/DNA induce CD8+ immunity through the
endogenous class I presentation pathway; however, other
vaccines require cross-presentation.21 Adjuvants have a number
of roles including enhanced presentation of antigens and direct
stimulation of an immune response using inactivated toxin or
virus components or other immune-stimulating molecules such
as bacterial lipopolysaccharides or Toll-like receptor agonists
including lipopeptides, as discussed in section 4.
Traditionally, alum has been used as a common vaccine
adjuvant, and recent reviews discuss other widely used inorganic
adjuvants; see, for example, refs 21, 22, and 29. Later
developments include oil-in-water emulsions such as Freund’s
complete adjuvant which contains heat-killed Mycobacterium
tuberculosis (incomplete Freund’s adjuvant lacks the mycobac-
teria) or squalene oil-in-water emulsions AS03 or MF59
(squalene is more readily metabolized than paraffin, used in
Freund’s adjuvants).21,22 Alum and emulsion adjuvants are
generally considered to have good safety profiles.21,30,31
However, Freund’s aduvant contains many innate immune
stimulants and can cause side serious effects; indeed, use of both
Freund’s complete and incomplete adjuvants was discontinued
for this reason.22,31−33
Organic adjuvants such as those based on peptides, proteins,
lipids, polysaccharides, and lipopeptides offer scope to tailor
more specific immune responses and are the focus of
considerable interest in the development of new vaccines.
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Research in the field of organic vaccine adjuvants has been
reviewed.21,31,34
3. LIGATED LIPOPEPTIDES
A series of lipopeptides (sequences given in ref 36) containing
palmitoyl chains at lysine ε-amino groups has been produced as
part of an HIV vaccine development program.36−38 Although
the conformation and self-assembly of these lipopeptides has not
been examined, they show promise as vaccines, since B and T
cell anti-HIV responses were detected in >85% of the vaccinated
volunteers after one month, and the research proceeded to
clinical trials.14,38,39 In another study, palmitoylation at the
lysine residue was also used to increase the immunogenicity of a
series of peptides derived from four malaria parasite P.
falciparum antigens.40 Again, although information on peptide
and lipopeptide conformation and ordering is not provided,
these molecules generate multi-epitopic and long-lasting
antigen-specific CD8+ CTL responses in chimpanzees, showing
potential also as human vaccines.40 N-Terminal lipidation
(palmitoylation) of the model antigen herpes simplex virus type
1 (HSV-1) gD1−23 peptide increases uptake and maturation of
dendritic cells via TLR2 and triggers Th1-dependent protective
immunity.41 The lipidation was performed by N-terminal
attachment of a single Nε-palmitoyl-lysine to the N-terminal
lysine ε-amino in the peptide using chemoselective ligation.41
This method avoids problems with solid phase lipidation
methods that arise due to the amphiphilicity of the lipopeptides
which can complicate solution separation of the target
lipopeptide.42 The method can be used to prepare mixtures of
lipopeptides (demonstrated with peptides based on simian
immunodeficiency virus fragments and a Clostridium tetani
sequence) and involves the site-specific introduction of a fatty
acyl moiety in solution to a mixture of individually prepurified
peptides.42 The lipidation is based on the quasi-stoichiometric
and high-yield ligation of a glyoxylyl lipid with hydrazinoacetyl
peptides. This method was used to produce the HIV lipopeptide
cocktails mentioned above, along with other antigen sequen-
ces.43−45 A modification of this method was used to attach three
N-terminal palmitoyl chains (via three K residues) to two
peptide epitopes in the development of a herpes simplex virus
vaccine for intravaginal delivery via the genital mucosa.35 The
peptide sequence includes CD4+ Th and CD8+ CTL sequences
(Scheme 1), and the attachment of one, two, or three palmitoyl
chains was motivated by the demonstrated TLR2 agonist
properties of related PamnCys lipopeptides (discussed in section
4).35,46
Scheme 1. Tri-Palmitoylated Lipopeptides Prepared with Dual-Function Epitopes35 a
aThe Pan DR peptide (PADRE) is a universal CD4+ epitope, and gB498−505 indicates the HSV glycoprotein B (gB) CD8
+ cytotoxic T cell
immunodominant epitope. Abbreviations: dA, L-alanine; Cha, L-cyclohexyl alanine; Ahx, aminocaproic acid. Reprinted by permission from Nature
Publishing Group.35 Copyright 2009.
Scheme 2. General Schematic of the Structure of PamnCys and MALP-2 Lipopeptides in Which the Peptide Is Linked via a
Cysteine-Based Unit to a Glycerol Moiety and One or More Lipid Chainsa
aChiral carbon centers are indicated by * and **. Based on ref 47.
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4. TOLL-LIKE RECEPTOR AGONIST LIPOPEPTIDES
Lipoproteins and lipopeptides are important components of the
cell wall of both Gram-negative and Gram-positive bacteria.
Gram-negative bacterial membranes tend to contain lip-
opeptides with three lipid chains, whereas Gram-positive cell
walls contain lipopeptides bearing two lipid chains.27 These are
heterogeneous in terms of fatty acid chain length and degree of
saturation. Lipoproteins derived from Gram-negative bacteria,
such as E. coli,49 Borrelia burgdorferi,50 Neisseria gonorrheae,51
Neisseria meningitidis (meningococcus),52 and Porphyromonas
gingivalis,53 have been shown to be TLR2 agonist triacylated
lipoproteins (N. meningitidis lipoproteins are the basis of the
vaccine Trumenba53). Lipoproteins from Gram-positive bac-
teria such as Staphylococcus aureus act on TLR2 and are
diacylated derivatives.54,55
A number of lipopeptide adjuvants have been developed
based on stimulation of TLRs. The core structure with one, two,
or three lipid chains linked through a glyceryl cysteine linker to a
peptide sequence is shown in Scheme 2, which shows the main
peptide sequences that have been used and developed
commercially. Peptide- and lipopeptide-based TLR agonist
systems for vaccine development have been re-
viewed.20,27,47,56,57 Tripalmitoyl-S-glyceryl cysteine (Pam3Cys)
is derived from the N-terminal moiety of Braun’s lipoprotein
that spans the inner and outer membranes of Gram-negative
bacteria. On the other hand, dipalmitoyl-S-glyceryl cysteine
(Pam2Cys) corresponds to the lipid moiety of macrophage-
activating lipopeptide 2 isolated from mycoplasma (bacteria
which lack cell walls). It has also been reported that Pam2Cys is a
more potent stimulator of splenocytes and macrophages than
Pam3Cys.
58 It also has a negligible pro-inflammatory response,
as assessed in terms of cytokine (TNF-α, IL-1β, IL-6, and IL-8)
release in a study using whole human blood.59 Pam3Cys
activates TLR2 to produce a Th2 response, as evidenced by the
production of associated effector molecules including IL-13 and
IL-1β but not Th1-related cytokines.60 Other groups found that
TLR2 stimulated by Pam3CSK4 promotes Th2 response,
61 as
well as that of Th17 which is implicated in several autoimmune
conditions.61−63 The TLR2 activation was found to occur via
other TLRs (TLR4 and TLR7/8), since cytokine production in
human DCs induced by these TLRs was inhibited by TLR2.61
These reports seem to be contradicted by another study, in
which it is reported that Pam3CSK4 and MALP-2 trigger Th1
cell function via TLR2 but do not stimulate any Th2 cell
response.64 The X-ray crystal structure of the Pam3Cys ligand
co-crystallized with the TLR1/2 dimer has been reported,65 as
has the crystal structure of Pam2CSK4 with the TLR2/TLR6
dimer.66
Figure 2.Cryo-TEM images of aqueous solution structures (2 wt % lipopeptide) of (a) PamCSK4, (b) Pam2CSK4, and (c) Pam3CSK4.
77 Published by
The Royal Society of Chemistry.
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In a pioneering paper, Braun reported that a lipoprotein
component of the outer membrane of E. coli is a specific and
potent antigen.67 This group had earlier identified
Pam3CSSNAK as the N-terminal domain from the murein
(peptidoglycan) lipoprotein obtained from the outer cell
membrane of E. coli.68,69 Shorter fragments of the SSNAK
peptide were also isolated,69 and synthetic lipopeptides bearing
these sequences were prepared. All of them were found to be
mitogenic and stimulated B lymphocytes into immunoglobulin
secretion, as shown by a hemolytic plaque assay.70,71 The activity
of all lipopeptides bearing different peptide fragments was
comparable to that of the native E. coli lipoprotein, although
those bearing only cysteine were hardly active.71 The
Pam3CSSNAK lipopeptide was shown to also have adjuvant
activity, as shown in a study of antibody response in sheep.72
This group also compared the activity of Pam3CSSNA,
Pam3CSK4, Pam3CAG, and Pam3CS, and all lipopeptides were
shown to have excellent adjuvant activity.73 The lipopeptide
Pam3CSK4 was found to be a potent antigen able to fully replace
Freund’s complete adjuvant (PCS) enhancing immunoglobulin
production in mice.73 Earlier studies on Pam3Cys-based
peptides with adjuvant or antibody-stimulating properties or
self-adjuvating forms have been summarized.74
Peptides and lipopeptides such as Pam2CSK4 and Pam3CSK4
were developed with enhanced amphiphilicity (compared to the
native E. coli murein lipoprotein), with the additional lysine
residues conferring solubility.73 These molecules are agonists of
TLR2 in particular and the Pam3Cys variants also with
TLR1.20,58,59,75,76 The peptide conformation and self-assembly
properties of the mono-, di-, and tri- palmitoylated CSK4
lipopeptides were compared using a combination of CD
spectroscopy, cryo-TEM, and SAXS.77 This revealed that
PamCSK4 and Pam2CSK4 form spherical micelles (Figure
2a,b) in which the peptide adopts an unordered conformation.
In contrast, Pam3CSK4 forms a population of nanotape
structures (Figure 2c), based on β-sheet aggregation (these
disorder on heating).77 The experimental findings were
confirmed by later atomistic molecular dynamics computer
simulations.78
Due to the potent immunogenic properties of PamnCys
lipopeptides, much work has been undertaken to determine the
structural features required for activity, as well as efforts to
improve the response. Jung and co-workers prepared a range of
analogues of Pam2CSK4 with variation in the length of the two
alkyl chains and analogues of Pam3CSK4 with different N-acyl
groups.79 They also determined the activity of the synthesized
lipopeptides using HEK293 cells transfected with human TLR2
and firefly luciferase reporter gene, measuring the release of IL-8
in the culture medium and NF-κB translocation using luciferase
reporter assay. They found that a critical length of more than
eight carbons in the two ester chains is required to elicit a
biological response, whereas the amide (N-acyl) chain length is
less important.79 Triacylated lipopeptides with short ester-
bound fatty acids such as PamOct2CSSNASK4 induce no
response in TLR1-deficient cells,80 and Pam2CSK4 and the C-
terminally elongated MALP-2 derivative Pam2CGNNDESN-
ISFKEKSK4(MALP2-SK4) induce cell activation in a TLR6-
independent manner.81 These molecules can be used as TLR-
independent controls in studies of immunogenic response. This
group also screened randomized Pam2Cys variants (Scheme 3)
for B cell proliferation activity using murine splenic
lymphocytes.82 This led to the identification of two lipopeptides,
Pam2CGQHHM-NH2 and Pam2CSSHHM-NH2, with en-
hanced activity compared to Pam3CSK4. As well as the variants
shown in Scheme 3, this group also investigated the effect of lipid
chain length from C6−C20 in Pam-Cys(Dhp)-SSNASKKKK-
based [Dhp: 3,4-dihydropyran] homologues, and the lip-
opeptide-induced IL-8 release from HEK 293-TLR2 cells was
assayed.83 The activity was found to be significantly reduced for
lipopeptides with lipid chain lengths shorter than C10. Ester-
bound oleic acid and/or linoleic acid gave the best results in the
IL-8 release assay.83
As mentioned above, a number of groups have investigated
structure−activity relationships in terms of the structure of the
S-(2,3-dihydroxypropyl)-L-cysteine linker present in several
TLR2 agonist lipopeptides. Scheme 4 summarizes the molecular
structures in these studies.20
Studying MALP-2 (Scheme 2), Takeuchi et al. reported the
significantly greater TLR2 activity of the R stereoisomer 4
(Scheme 4) compared to the S version 5, based on the analysis of
cytokines, chemokines, or NO released by cells.84 Substitution
of the thioether moiety with either a methylene (6)85,86 or
oxyether (7)87 group leads to a loss in TLR2 activity, whereas
substitution of S with Se (in 8) causes an upregulation of p38
mitogen-activated kinase (p38MAPK) in neutrophils.88 The R-
cysteinyl form of Pam2CSK4 is also maximally active in reporter
Scheme 3. Pam2Cys Variants Studied by Wiesmüller and
Coworkersa
aHere X is one of the 20 standard amino acids and O is any of these
amino acids except cysteine.82 Copyright 2005 John Wiley and Sons
Inc.
Scheme 4. Summary of Molecular Structures from
Structure−Activity Relationship Studies on TLR2 Agonist
Lipopeptides Based on the S-(2,3-Dihydroxypropyl)-L-
cysteine Core Present in Pam2CSK4 and PamCSK4
20
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gene assays using human TLR2, as revealed in a study of the role
of the highly conserved Cys residue as well as the geometry and
stereochemistry of the Cys-Ser dipeptide unit.87
Changing the length of the spacer between the thioether and
the α-center of cysteine (9 containing a penicillamine-based
linker or homocysteine-based 10) leads to dramatic reductions
in TLR2 activity.88 Substitution of the ester functionalities for
amide (in 11)89 or ether (in 12)90 groups in lanthionine
scaffolds strongly inhibits TLR2 activity. Compound 13
(corresponding to PamCys, Scheme 2) has pronounced TLR2
agonist activity.88 However, inversion of the ester bond (in 14
and 15) or extension of the chain between the thioether and
ester groups leads (in 16) to a significant reduction in activity.88
A derivative with a thioethanol bridge in place of the thiogylcerol
unit retained TLR2-specific NF-κB induction activity.88 The
role of stereochemistry (R- and S-stereoisomers of the glycerol
moiety) has been examined for Pam3CSK4, and it was found that
the R-stereoisomer has greater activity,74,91 similar to the case of
MALP-2. This was ascribed to enhanced TLR2 triggering due to
greater DC activation which stimulates CD8+ T cell responses,
in particular higher IL-12 secretion, and upregulates relevant
markers for DCmaturation.91 Methylene substitution [to give 2-
(palmitoylamino)-6,7-bis(palmitoyloxy)heptanoic acid) (6)]
leads to lower activity than Pam3CSK4 at a given concentration,
although the maximal activity obtained at significantly higher
concentration is similar to that of Pam3CSK4.
86 The role of
stereochemistry was also examined, all four stereoisomers being
prepared, the 6S form was active in terms of radiolabeled
[3H]thymidine incorporation (a cell proliferation assay) into the
DNA of mice splenocytes after stimulation with lipopeptides
than the 6R form, with little influence of the other (2S/2R)
stereocenter.86 The authors also noted that these lipopeptides
constitute potent macrophage activators with anticancer
activity: in particular, the (2S,6S) stereoisomeric form was
able to induce tumor cytotoxicity.86 Further details of the
synthesis of the derivatives discussed in this section are provided
by Brimble and co-workers.20,57
A series of Pam2CSK4 analogues (Scheme 5) were prepared
that contain a urea (carbamyl) linker (hence, they were termed
UPam) to one lipid chain and a range of substitutions for the
serine residue.92 The motivation for the N-tetradecylcarbamyl
substitution was the expectation that immunostimulatory
activity would be enhanced, on the basis of modeling of the
crystal structure of the X-ray structure of the Pam3Cys ligand co-
crystallized with the TLR1/2 dimer.65 Probing DC maturation,
the authors observed that UPam derivatives 3−5, 7, 9, and 10
(Scheme 5), which contain small, mostly hydrophobic side
chains substituting for the hydroxymethyl of 1 (UPam-Ser),
show an increased potency compared to Pam3CSK4 and those
containing amino acids with straight alkyl chains of moderate
size terminated with a polar functional group (12 and 13) also
have enhanced activity (compared to Pam3CSK4). In contrast,
the derivatives 8, 14, 15, 20, and 22 were found to have minimal
activity.92
Lipopeptide Pam3CSK4 has been investigated as an adjuvant.
For example, it can elicit immunogenicity, i.e., CTL responses to
Plasmodium berghei circumsporozoite (CS, a parasite that can
cause malaria in rodents) peptide epitope SYIPSAEKI either in
mixtures or by conjugation of this sequence onto Pam3CSK4 (to
give Pam3CSK4SYIPSAEKI), as assayed using mouse spleno-
cytes.93 In addition, a conjugate of Pam3Cys with poly(ethylene
glycol) (PEG) also known as polyoxyethylene (the synthesis of
the conjugate being described earlier94) was investigated as part
of the range of formulations studied, and this conjugate mixed
with CS also generated a CTL response.93 The influence of the
structure of Pam2Cys analogues on TLR2 agonist activity
prepared as potential adjuvants for cancer vaccines has been
examined.20 The effects of homologation between the two ester
functionalities, N-terminal acylation, and acyl group stereo-
chemistry (Scheme 6) were examined in lipopeptides bearing
the SK4 sequence linked to an epitope from the tumor associated
NY-ESO-1 protein based on the sequence SLLMWITQC
(Scheme 6b).20 For the bioactivity assays, HEK-Blue-hTLR2
cells were transfected with the TLR2-NF-κB-SEAP reporter-
gene system. This system has been taken forward into
commercial development by SapVax.95 Pam3CSK4 has also
been used in the development of anHIV vaccine, by conjugation
to the 32-amino-acid group-specific antigen peptide containing
at least five CTL epitopes, NPPIPVGEIYKRWIILGLNKIVRM-
YSPTSILD.96
Direct thiol−ene coupling has been used to alkylate CSK4
with an S-palmitoyl chain at the N-terminus.97,98 In addition, as
a model vaccine cytomegalovirus (CMV) ppUL83 protein
sequence NLVPMVATV99 was attached to produce an
antigenic lipopeptide bearing the SK4NLVPMVATV sequence.
Strong up-regulation of the co-stimulatory molecule CD80 on
human monocytes in fresh blood samples was observed using
Scheme 5. Urea-Functionalized Pam2Cys Analogues (UPam
Derivatives) Studied by Willems et al.92
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flow cytometry, higher than that for Pam3CSK4.
97,98 This
reaction was later studied in more detail, due to the presence of
an observed byproduct (shown in Scheme 7), and conditions to
obtain either mono- or bis-palmitoylated cysteine derivatives
were identified.100 The molecule in Scheme 7 is a homologue of
Pam2Cys with an extra methyl group in the glyceryl linker and
was termed homoPam2Cys. It was isolated as a mixture of
stereoisomers and was tested for NF-κB induction, and it
showed the same activity as Pam2Cys itself.
20 The effect of the
stereochemistry was investigated by preparing R and S
enantiomers of Pam2Cys, homoPam2Cys, and analogues.
20
Based on the NY-ESO-1 protein sequence SLLMWITQC
mentioned above and the HEK-Blue TLR2 reporter system, it
was found that the R diastereomers have activity, whereas the S
versions show a pronounced reduction in TLR2 activity.20
Derivatives based on Pam2Cys bearing branched highly
cationic or anionic N-termini have been designed (Scheme 8) in
order to facilitate interaction with oppositely charged soluble
protein antigens.101,102 The binding of lipopeptide to oppositely
charged antigens leads to the formation of complexes at
physiological pH.101 The complexes elicit a CD8+ T cell
immune response in mice, with concomitant pro-inflammatory
cytokine production. Model antigens selected were ovalbumin
(OVA) or hen egg lysozyme (HEL) with a net calculated charge
of −11 or +8, respectively. The complexes were also shown to
protect vaccinated mice against challenge with a live chimeric
influenza virus engineered to contain the OVA CTL epitope
SIINFEKL. The induced CD8+ T cell response correlated with
the ability of lipopeptide to facilitate antigen uptake by dendritic
cells (DCs). Oppositely charged lipopeptides were more
effective in DC uptake and trafficking. Substantial antibody
titers were produced by vaccination with complexes composed
of oppositely charged lipopeptide and protein, whereas
innoculation with similarly charged constituents resulted in
Scheme 6. Pam2CSK4-Based Lipopeptide Molecular Structures Studied by Brimble’s Group
20 a
a(a) Schematic of the architecture, (b) molecular structures of specific molecules investigated.
Scheme 7. Homologue of Pam2Cys Termed homoPam2Cys
Prepared by Brimble’s Group20
Scheme 8. (a) R4Pam2Cys, (b) E8Pam2Cys
101 a
aOriginally published in The Journal of Immunology. Copyright 2011
The American Association of Immunologists, Inc.
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measurable but lower antibody production.101 Peptide
R4Pam2Cys (Scheme 8) shows a strong ability to bind OVA,
leading to the formation of large complexes (ca. 400 nm radius
from DLS).102 Excellent adjuvant activity was noted, from
measurements of antibodies in mice and cytokine production.
Antibody titers were higher for the lipopeptide/OVA mixture
than those elicited by OVA in the presence of alum and were
comparable to those elicited by OVA formulated with complete
Freund’s adjuvant (CFA). The activity of the D-Arg homologue
of R4Pam2Cys was also examined and was shown to stimulate
similar levels of antibody production, although CD8+ T cell
responses (IFN-γ secretion) were reduced.102 Covalent
conjugates of Pam3CSK4 with OVA247−264 peptide epitope
DEVSGLEQLESIINFEKL (or another peptide with this
sequence and an A5K C-terminal extension) were prepared in
a study of the TLR2 processing.103 It was found that the uptake
of the conjugates is TLR-independent, and inhibition of
clathrin- or caveolin-dependent endocytosis greatly reduced
uptake and antigen presentation of the Pam3CSK4 conjugates.
The lipopeptides induce a strong and specific T cell response
due to the combined effects of enhanced antigen uptake,
improved MHC class I antigen presentation, and dendritic cell
maturation.103 The Pam2Cys scaffold has been employed in the
development of a range of immunogenic lipopeptides. In one
example focused on the development of self-adjuvanting
immunocontraceptive vaccines, Pam2Cys linkers (incorporated
via lysine ε-amino units) were compared to Pam3Cys and
control sequences just bearing lysine linkers, or other constructs
with only C-terminal peptide sequences.58 These bifunctional
lipopeptides bear both the LHRH (luteinizing hormone
releasing hormone) sequence EHWSYGLRPG and a T-helper
epitopeGALNNRFQIKGVELKS (from the L chain of influenza
virus hemagglutinin). The lipopeptides induce antibodies
against the “self” hormone LHRH in inoculated mice, without
requiring additional adjuvant. The Pam2CSS lipopeptide
attached laterally via a central K residue linking the two epitopes
was highly effective, inducing high antibody titers, which were
able to efficiently sterilize female mice when administered in
saline by s.c. or intranasal routes.58 The architecture with
pendant PamnCSS linked via the ε-amine group of lysine
(Scheme 9) is also most effective in stimulating DC maturation
via TLR2.104 This was confirmed in a study using lipopeptides
with this architecture bearing a Th sequence ALNNRFQIKGV-
ELKS from influenza hemeagglutinin that elicits CD4+ T cells
and a CTL peptide epitope TYQRTRALV, i.e., NP147−155,
derived from the nucleoprotein of the influenza virus which is
the dominant CD8+ T cell epitope recognized by BALB/c mice
in all type A influenza strains.104
In another example, bifunctional Pam2Cys-based derivatives
were designed as a self-adjuvanting vaccine that induces
neutralizing antibodies against heat-stable enterotoxin from
enterotoxigenic E. coli.105 Three constructs were synthesized
with an N-terminal helper T cell epitope (GALNNRFQIKGV-
ELKS, as above) and a C-terminal heat-stable enterotoxin (ST)
tricylic peptide106 NSSNYCCELCCNPACTGCY (C6−C11,
C7−16, and C10−C18 disulfide links) with different linker
groups to the ST peptide (Scheme 10). All three compounds
generated specific anti-ST antibodies; however, the low titer
antibodies (using a mouse model) induced by the oxime-
containing derivative demonstrated better neutralizing activity
when administered via the intranasal mucosal route.105 As
pointed out byMoyle and Toth,47 the delivery of antigens mixed
with, or conjugated to, lipopeptide adjuvants has the potential to
produce vaccines that are immunogenic via mucosal routes, in
particular nasal or oral.
The Jackson group showed that in fact this modular approach
can be extended to produce immunogenic lipopeptides bearing
LHRH or acid polymerase (PA) of influenza virus with sequence
SSLENFRAYV or the ST enterotoxin mentioned above linked
by oxime, thioether, or disulfide units to one of three T helper
cell motifs.107 The first was Th(OVA) derived from OVA, with
sequence ISQAVHAAHAEINEAGR, the second was Th(FLU),
Scheme 9. Architectures of Dual-Action Th- and CTL-Containing Lipopeptide Constructs Bearing PamnCys Units Studied by
Jackson’s Group104 a
aReprinted by permission from Oxford University Press.
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which is derived from the light chain of influenza virus
hemagglutinin (sequence ALNNRFQIKGVELKS), and the
third was Th(MV), derived from the fusion protein of the
Morbillivirus canine distemper virus (sequence KLIPNASL-
IENCTKAEL). The authors note that using a thioether bond to
conjugate the two components has the advantage of simpler
chemistry and somewhat higher yield of product, whereas
disulfide or oxime bond formation requires an additional
synthesis step. Oxime bond formation, however, does have the
advantage that the unwanted side products resulting from thiol
groups present in cysteine residues (if present) may be avoided.
The antibody and CD8+ T cell responses were found to depend
on both the linker group and the Th epitope employed.107 In a
related study, the Th sequence LNNRFQIKGVELK derived
from the light chain of influenza hemagglutinin was linked via
the same linker with appended Pam2CSS (Scheme 9) to the
CTL epitope, with sequence TYQRTRALV, mentioned
above.108 The Th domain was selected because it elicits CD4+
T cells that are cross-reactive with all H3 influenza viruses and
the CTL (CD8+) epitope is common to all type A influenza
strains. This lipopeptide can be delivered intranasally and is able
to prime lung-resident memory CD8+ T cells for long-term
pulmonary protection against influenza.108 In another case,
three Pam2Cys-based conjugates were prepared which contain a
solubilizing spacer composed of either sequences of lysine
residues or polyethylene glycol (PEG).109 The model proteins
HEL or bovine insulin were lipidated with the three types of
lipid-spacer moieties, and the immunogenicity of the lipidated
species was determined in mice by measuring antibody
responses. The lipopeptides contain C-terminal cysteine
residues which allow for formation of either a thioether or a
disulfide bond with proteins (or peptides) derivatized withMCS
[N-(ε-maleimidocaproyloxy acid succinimide ester] or SPDP
[succinimidyl 3-(2-pyridyldithio)propionate], respectively.109
The Pam2Cys scaffold has been used to attach both helper T cell
Th and a target epitope that is either recognized by CD8+ T cells
or B cells, using a diversity of Th and target epitopes.110 These
examples highlight research showing that the modular
(“subunit”) approach to the self-adjuvant vaccine development
offers considerable scope to tune the immune response. A review
is available that details methods to synthesize the lipopeptides
designed by the Jackson group.111
The Pam3CSS scaffold has been used along with the 16 N-
terminal amino acids of theM. tuberculosis 19 kDa lipoprotein to
give Pam3CSSNKSTTGSGETTTAwhich has been shown to be
an agonist of RP105, a member of the TLR family that interacts
with TLR2 and facilitates recognition of mature lipoproteins
expressed bymycobacteria.112 Mono- and dipalmityol analogues
were also examined, as were peptide variants. These studies
showed that, although the lipid moiety is required for
macrophage activation, it is not a determinant of RP105
dependency. However, substitution of the T7 and T8 residues
with nonpolar alanine residues led to reduced RP105 depend-
ency.112
Like Pam3CSK4, the M. tuberculosis 19 kDa lipoprotein
(lipopeptide) stimulates T cell proliferation via TLR2 activity,
producing IFN-γ in an accessory cell-dependent manner. Sieling
et al. compared the activities of these two lipopeptides along
with the Treponema pallidum lipoprotein TP47.75 Treponema
pallidum and Borrelia burgdorferi are the spirochetal pathogens
responsible for syphilis and Lyme disease, respectively, and
lipoproteins from the membranes of these organisms elicit a
strong immunoinflammatory response, as potent activators of
monocytes/macrophages.113,114 The OspA outer surface
protein from B. burgderfori contains a post-translational
amino-terminal Pam3Cys lipid moiety, and this component is
essential in producing an antibody response.115 The full OspA
lipoprotein showed significantly better adjuvant activity than
Pam3CSK4 in a study of intranasal delivery. Synthetic
lipohexapeptides corresponding to the N termini of the B.
burgdorferi strain B31 OspA lipoprotein (CKQNVS) and the T.
pallidum subspecies pallidum 47-kDa lipoprotein (CGSSHH)
prepared as glyceryl cysteine derivatives (with a Pam3C motif)
show similar activity, as does the unlipidated OspA hexapep-
tide.114 The binding domains of the p19 M. tuberculosis 19 kDa
lipoprotein to MHC class I binding motifs H-2Db and H-2Ld
have been identified.116 Several samples from a series of
PamCSS-based lipopeptides investigated elicit a CTL response,
assayed as IFN-γ production from mouse splenocytes; in
particular, lipopeptides which upregulated MHC-I molecules
(with a H-2Db binding motif) showed this activity.116
Self-adjuvant breast cancer vaccines based on Pam3CSK4 were
prepared using the HER2 (human epidermal growth factor
receptor-2) epitope CH401, YQDTILWKDIFHKNNQ-
LALT.117 Other formulations included a lipopeptide based on
this sequence in a single palmitoylated peptide with a diethylene
glycol linker and mixtures of this with Pam3CSK4 or the
Scheme 10. Lipopeptide Conjugates Prepared by the Jackson
Group with Different Linkers between a Helper T Cell
Domain (Th) and the Heat-Stable Enterotoxin ST Domaina
aThe Pam2Cys (P2C) unit is attached laterally via a KSS linker.
Reprinted from ref 105 with permission. Copyright 2012 Elsevier.
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sphingolipid α-GalCer (a strong immunostimulant with
antitumor properties) or Lipid A or a Pam-Th epitope
QYIKANSKFIGITE (tetanus toxin-derived epitope). The
conjugate self-adjuvanting vaccine produced a stronger antibody
response (IgG titers from mice) than that of Pam3CSK4 itself.
The conjugate Pam3CKS4−CH401 conjugate self-assembles
into globular aggregates, as revealed by TEM, whereas mixtures
of PamCSK4 and Pam-CH401 showed fibrillar co-assemblies,
also observed for other mixtures containing Pam-CH401. The
co-assembled structures also elicited a robust immune
response.117
The conformational and self-assembly properties of MALP-2
have been examined in detail.118 MALP-2 is a macrophage-
activating lipopeptide (hence the name) originally isolated from
Mycoplasma fermentas and contains a 13-residue peptide
GNNDESNISFKEK attached to a Pam2Cys linker (Scheme
2).119 Whereas three lipid chain lipopeptides such as Pam3CSK4
signal via TLR1 and TLR2 as discussed above,20,48,58,59,75,76
MALP-2, in common with other two-lipid-chain lipopeptides,27
signals via TLR2/TLR6 heterodimers with CD36 as co-
receptor.76,120,121 Both MALP-2 and the constituent peptide
adopt β-sheet conformations with different morphologies, with
MALP-2 forming fibril rafts, whereas the peptide alone forms
nanotape structures.118 Pro-inflammatory responses in mouse
lungs induced by MALP-2 and Pam3CSK4 have been compared,
considering the fact that the lungs have the highest expression of
TLR2 receptors. The authors observed that the MALP-2-
dependent induction of Tnc (tenascin C, a glycoprotein
involved in inflammation) may indicate the existence of
TLR2/6-specific pathways.76 The recognition of MALP-2 by
TLR6 cooperatively with TLR2 was noted, together with the
observation that TLR6 appears to discriminate between the N-
terminal lipidated structures of MALP-2 and Pam3CSK4.
120
Indeed, by comparing MALP-2 with the variant of MALP-2
containing three rather than two palmitoyl chains, it was inferred
that three-chain lipopeptides are recognized by TLR2while two-
chain molecules (MALP-2 or lipoteichoic acid) require
additional cooperation with TLR6.121 In subsequent work,
Mühlradt’s group compared the macrophage-stimulating
activities of two lipopeptides isolated fromMycoplasma hyorhinis
and several synthetic peptides including Pam2CSK4 and
Pam3CSK4 with MALP-2.
122 The assays measured nitric oxide
release assay with peritoneal macrophages from C3H/HeJ mice.
The isolated peptides were analogues of MALP-2 containing (in
some cases) different lipid chains (and in all cases different
peptide sequences), i.e., S-[2,3-bisacyl(C16:0/C18:0)oxy-
propyl]cysteinyl-GQTDNNSSQSQQPGSGTTNT and S-[2,3-
bisacyl (C16:0/C18:0)oxypropyl]cysteinyl-GQTN and an
additional synthetic peptide S-[2,3-bis(palmitoyloxy)propyl]-
cysteinyl-GQTNT was examined. The GQTNT motif is from
the determined variable lipopeptide C (VlpC) sequence. The
lipopeptides showed pM activity, i.e., were as active as MALP-2,
except for Pam3CSK4 which showed activity above 100 pM.
122 A
PEGylated version of MALP-2 has been shown to produce
strong humoral and cellular immune responses against enter-
ohemorragic E. coli after intranasal vaccination in a mixture with
enterohemorragic E. coli antigens.123 The MALP-2 derivative
was effective as an adjuvant in this mucosal (nasal) vaccine study
due to its improved solubility. MALP-2 has also been used in
combination with gemcitabine (a chemotherapy medication) in
a phase I/II clinical trial of an immunotherapy for patients with
pancreatic carcinoma.15 Lipopeptides have also been derived
from the 44 kDa membrane-bound lipoprotein of Mycoplasma
salivarium, including the N-terminal lipopeptide S-(2,3-bisacyl-
oxypropyl)-cysteine-GDPKHPKSFTEWVA-, which was used as
the basis to create the synthetic analogue S-(2,3-bispalmitoyl-
oxypropyl)-cysteine-GDPKHPKSF.124,125 The latter is com-
mercially available as FSL-1 (fibroblast-stimulating lipopep-
tide)125 and, like other Mycoplasma derivatives such as MALP-
2, is recognized by TLR2 and TLR6.126 Variants of FSL-1 with a
substitution of the C-terminal F for R or substitution of the
palmitoyl lipid chains for stearoyl chains were also reported.126
The fact that TLR2/6 agonists can reduce virus levels in the
upper respiratory tract has motivated the recent investigation of
the use of a Pam2Cys analogue in the treatment of COVID-19
caused by the SARS-Cov-2 virus.127 Intranasal prophylactic
administration of a compound INNA-051, a PEGylated
Pam2Cys analogue (structure not disclosed but related to that
shown in ref 109), was shown to reduce SARS-CoV-2
transmission and to provide protection against COVID-19.
Stimulation of TLR2 leads to activation of the innate immune
response, reduced inflammation and tissue damage, and
improved local epithelial barrier function.127 However, inves-
tigating respiratory syncytial virus infections, Nguyen et al.
concluded that modulation of infection using Pam3CSK4 is
independent of TLR activation.128 This was based on the
observation that two structurally related lipopeptides
(PamCSK4 and PHCSK, a negative control for Pam3CSK4
lacking a methylene group in the thioether spacer) without
TLR-signaling capacity did modulate RSV infection, whereas
Pam3CSK4-based TLR1/2 agonists did not.
128 Studying
COVID-19 disease severity and its relationship to TLR2
Scheme 11. Conjugates of a 2-Alkoxy-8-hydroxyadenyl Derivative (1) with Peptides (3−5) Prepared by Weterings et al.130 a
aIn the conjugates, the 2-alkoxy-8-hydroxy adenine group is shown in red, while green indicates the linker region resulting from the Cu-catalyzed
click cycloaddition reaction (via the azide unit in 2). The OVA peptide sequence SIINFEKL is shown in bold. Reprinted from ref 130 with
permission. Copyright 2006 Elsevier.
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signaling, Zheng et al. identified an optimal TLR2 inhibitor by
confirming the effectiveness and specificity of two different
inhibitors of TLR2 signaling in bone-marrow-derived macro-
phage stimulated with Pam3CSK4.
129 Thus, Pam3CSK4 has
utility as a model agonist in studies on TLR2 inhibitors for
COVID-19 vaccine development.
Conjugates of peptides with nucleotides have been prepared
as TLR-dependent immunogens. In one example, the 2-alkoxy-
8-hydroxyadenylpeptide conjugates shown in Scheme 11 were
prepared.130 The nucleotide component is believed to act as a
TLR7 ligand. These conjugates bear the MHC class I epitope
SIINFEKL from OVA. In comparison with a mixture of their
individual components, these conjugates gave rise to enhanced
antigen presentation in vitro but were found not to be able to
induce DC activation.
5. LIPID CORE PEPTIDES
Toth’s group has developed so-called lipid core peptide (LCP)
systems to deliver peptide epitopes at high density for a variety of
applications, including the development of self-adjuvant
vaccines.47,131 Scheme 12 shows an example from a study that
aimed to develop a peptide-subunit-based vaccine for hook-
worm infection.132 The LCP in this example comprises three
lipidic amino acid chains and a four-arm amine functionalized
Scheme 12. Structure of Lipid Core Peptide (LCP) Derivatives Developed as a Peptide-Based Subunit Vaccine against
Hookworm Infection132
Scheme 13. (A−C) Lipopeptide and (D) LCP Constructs Based on Lipoamino Acids (LAAs) and the J14 and P25 Peptide
Epitopes Discussed in the Text136
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dendrimer. The constructs prepared bear one of two peptide
epitopes shown in Scheme 12. One is a B cell peptide epitope
from the apical enzyme in the hemoglobin digestion cascade, the
aspartic protease Na-APR-1 termed A291Y (peptide 1, Scheme
12), while chimeric peptide 2 contains the A291Y sequence
flanked on either side by helix-promoting sequences from the
yeast GCN4 protein. It was found that, while A291Y alone or the
chimeric peptide with or without Freund’s adjuvants induce
negligible antibody responses, the LCP construct incorporating
the chimeric peptide induces a strong IgG response in mice. The
active chimeric peptide was designed to induce the native helical
A291Y epitope conformation.132
This group also developed lipopeptide-based conjugates in an
effort to produce a Group A Streptococcus (GAS) vac-
cine.133−136 The architectures of other constructs prepared by
this group are shown in Scheme 13, and all contain the J14
peptide epitope KQAEKVKASREAKKQVEKALEQLEDKVK,
in which the 14-residue peptide GASM-protein C region (B cell
epitope) is shown in bold, along with a universal helper T cell
epitope KLIPNASLIENCTKAEL (P25). The LCP D in
Scheme 13 contains two copies of J14 and P25. The vaccine
of type A (Scheme 13) featuring a C-terminal palmitoyl lipid
moiety, with P25 located at the N-terminus, and J14 attached to
the side chain of a central lysine residue was capable of inducing
the optimal antibody response after intranasal immunization in
mice.133,136 This group had earlier developed a LPC bearing the
88/30 GAS sequence DNGKAIYERARERALQELGC and the
J8 GAS peptide sequence QAEDKVKQSREAKKQVEKALK-
QLEDKVQ (with bold core sequence related to that in J14) in
the development of a self-adjuvant intranasal vaccine targeting
the GAS M protein.137,138 The LCP vaccine formulation
induced the elicitation of antigen-specific IgG production
when administered with or without mucosal adjuvant cholera
toxin B subunit, whereas cholera toxin B subunit was required
for the induction of antigens. This group also developed human
papilloma virus (HPV) vaccines based on an LCP bearing four
copies of a 19 amino acid long sequence QAEPDRAHYNIV-
TFCCKCD E744−762 from the HPV16 E7 protein.
139 The sugar
D-mannose was conjugated (N-terminally) to the LCP
molecules to probe the effect of targeting dendritic cell mannose
receptors on vaccine efficacy. The vaccines were able to clear or
reduce the size of HPV-16 associated tumors in mice, the
conjugates bearing mannose causing clearance or reduction in
size of tumors to a greater extent than non-mannose-containing
vaccines.139 LCPs can be prepared by native chemical ligation
(NCL), as exemplified in a study in which four copies of the
thioester-modified 88/30 GAS peptide antigen (with C to P
terminal residue substitution) were ligated using a C-terminal
mercaptopropionic acid leucine inker onto an LCP scaffold
featuring four cysteine residues.140 In another report, multiple
peptide epitopes including two 88/30 GAS epitopes, the J8
sequence, and PL1 VLTRRQSQDPKYVTQRIS, an S. pyogenes
antigen, were attached to an LCP framework using NCL.141,142
Studies with mice revealed that high levels of systemic IgG
antibodies were elicited against each of the incorporated
peptides.141 A triepitopic analogue with just one 88/30 GAS
peptide attached was also prepared, and its immune response in
terms of antibody titers and dendritic cell activation was
assayed.143,144
6. LIPOPEPTIDE MICELLES
Lipopeptide micelles have been developed as nanoparticles for
self-adjuvant vaccines to treat Herpes simplex virus (HSV)
infection.145 The micelles (presumably spherical) self-as-
sembled from PAs containing HSV envelope glycoprotein B
(gB) and glycoprotein D (gD) fragments. The critical micelle
concentrations were obtained from fluorescence probe assays,
and micelles were sized using dynamic light scattering. The
Table 1. HSV Fragment Peptides gB498−505 (1) and gD301−309 (2) and PA Constructs Containing These Fragments (3−5) That
FormHSV-Responsive ImmunomodulatoryMicelles, asWell as the AdOOCore Structure 6 [AdOO: 8-Amino-3,6-dioxaoctanoic
Acid]a
aRef 145 (Copyright Dove Medical Press).
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sequences and molecular structures of the PAs are shown in
Table 1. The peptide conformation was found from CD
spectroscopy to be unordered, both for single and mixed
[(C18)2L-gB498−505 and (C18)2L-gD301−309] peptide systems.
The micelles (as well as the peptides) were shown to
significantly raise in vitro levels of cytokines including
interleukins (IL-6, IL-8, IL-17, and IL-23), macrophage
inflammatory protein (MIP-2), and tissue necrosis factor
TNF-α.145
Lipopeptides that form cylindrical micelles have been shown
to generate a strong IgG1 antibody response, and these peptide
amphiphiles bearing a GAS B cell antigen act as self-adjuvanting
vaccines for infections caused by these bacteria.146 The peptide
having a α-helical structure was conjugated to a dialkyl
(dipalmitoyl, di-C16) chain. The micelles were shown not to
stimulate the pathogen-recognition receptor TLR2 in vitro,
indicating that this is not the origin of the self-adjuvancy, in
contrast to the Pam3CSK4 TLR agonist used for comparison
(section 4); instead, this was ascribed to the nanoparticle-
mediated delivery of the peptide epitope. Thus, the lipopeptide
system is non-immunogenic.146 The Tirrell group also
developed a micelle-forming lipopeptide containing a cytotoxic
T cell epitope (SIINFEKL from OVA, discussed in section 4),
linked to a di-palmitoyl (diC16) chain.
147 This molecule forms
rod-like micelles which have a self-adjuvant property and which
were shown to act not via TLR2 but instead they likely enhance
uptake by DCs by anchoring of the hydrophobic tails into cell
membranes. In addition, the micelles induce an immune
response by acting as antigen depots and providing a high
density surface presenting the epitopes and reducing degrada-
tion.147 The lipopeptides induce an antitumor antibody
response in mice immunized with the micelles, in particular a
reduction in tumor volume, improved survival rate, and
cytotoxic T cell response.147
7. CONCLUDING REMARKS
As the studies in this Review make clear, lipopeptides have
considerable potential to play a valuable role in the development
of vaccines, as antigens and/or adjuvants. There are pros and
cons to the use of lipopeptides. Advantages include the ease of
design and synthesis (and ability to perform large scale
syntheses) of peptides along with the ability to tune
conformation and self-assembly by lipidation, using established
physicochemical principles. As also highlighted herein, there is
scope to design active lipopeptides with a variety of
architectures, i.e., configurations of lipids and peptides. In
addition, lipopeptides offer the potential to tailor highly specific
responses that can be achieved by precision sequence engineer-
ing and lipopeptide architecture. Other positives include the
ability to prepare peptides at high purity, avoiding biological
contamination and reduced allergic response. Disadvantages
include the lack of the three-dimensional folded structure of a
protein and hence restricted binding properties to human cells
compared to actual antigens such as virus coat proteins. In
addition, peptides containing native L-amino acid residues are
susceptible to proteolysis and they can also have low
immunogenicity. The limited stability of peptides in vivo can
be overcome by a variety of strategies using non-natural amino
acids, cyclization, etc.13,16 In addition, lipidation enhances
stability in vivo, since it confers albumin-binding properties
which enable longer circulation without degradation.13,148−152
Lipopeptides have as yet found limited practical use in vaccines,
although a considerable number of peptide and lipopeptide
immunotherapies are in development.16−19
To be developed for practical uses, immune responses in
humans should be studied as part of later stage clinical trials.
Most research discussed above has focused on in vitro studies
and those using rodent models of immune response. However,
there can be significant differences in the PRRs presented in
human and animal cells. The use of humanized mice or
nonhuman primates as better models has thus been proposed.
Also, the delivery route for many animal studies differs from the
subcutaneous or intramuscular delivery used for practical
vaccine delivery.21 It has also been pointed out that the dose
in many animal studies may differ substantially from that
applicable to human use. A further limitation is the use of cell
culture methods for in vitro studies, since these do not detect
inflammatory responses generated by noncirculating tissue
cells.21
The choice of antigen used together with a particular adjuvant
will affect the response of DCs, for example whether a whole
protein or fragment antigen such as peptide sequences discussed
in this Review is selected. As highlighted in this Review, the
presentation of the antigen at the surface of a self-assembled
structure such as those formed by lipopeptides can also influence
the immune response. In many of the cases discussed in this
Review, the self-assembly and conformation of the lipopeptides
has not been examined, and this is a subject worth further
examination, since self-assembly may have a significant effect on
bioactivity.
For successful application, lipopeptide-based adjuvants and
antigens will clearly need to have an excellent safety profile.
Fortunately, current adjuvanted nonlive vaccines (i.e., the type
corresponding to lipopeptides) are considered to generally be
insufficiently immunogenic to trigger autoimmunity. This has
been well established for the widely used oil-in-water adjuvants
MF59 and AS03,21 and as discussed herein, some lipopeptide
systems have been developed to the stage of clinical trials and do
not seem to cause serious adverse reactions.
As mentioned in section 4, TLRs including those that are
agonized by lipopeptides such as the PamnCys type are
important in COVID-19 pathogenesis,153,154 and this has led
to a Pam2Cys-based intranasal prophylactic INNA-051 which is
under commercial development.127 This area is likely to be the
focus of further intense research activity as the current pandemic
continues to have major global effects. As outlined in this
Review, lipopeptides also hold great promise in the development
of vaccine treatments for many other serious infectious diseases
and cancer, and thus have the potential to deliver valuable novel
therapeutics based on a diversity of modes of action.
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(119)Mühlradt, P. F., Kiess, M.,Meyer, H., Süssmuth, R., and Jung, G.
(1997) Isolation, structure elucidation, and synthesis of a macrophage
stimulatory lipopeptide from Mycoplasma fermentans acting at
picomolar concentration. J. Exp. Med. 185, 1951−1958.
(120) Takeuchi, O., Kawai, T., Muhlradt, P. F., Morr, M., Radolf, J. D.,
Zychlinsky, A., Takeda, K., and Akira, S. (2001) Discrimination of
bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13, 933−
940.
(121)Morr,M., Takechi, O., Akira, S., Simon,M.M., andMühlradt, P.
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